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Summary. An increase in cyclic nucleotide monophos- 
phate levels is suggested to play a prominent role in 
mediating smooth-muscle r laxation. Cyclic nucleotide 
phosphodiesterase (PDE) influences mooth-muscle tone 
by decreasing the level of cyclic nucleotides. At present, 
five different families of isoenzymes of PDE exist that 
show a distinct species- and organ-specific distribution. 
Our study was done to evaluate the existence of specific 
PDE isoenzymes and its functional role in human ureteral 
tissue. Normal ureteral tissue was homogenized and 
centrifuged and the supernatant fraction wasseparated us- 
ing anioin-exchange diethylaminoethyl (DEAE)-Sephacel 
chromatography. A PDE assay was then performed and 
the peak fractions were added to different specific PDE 
activators and inhibitors. In vitro, longitudinal ureteral 
strips were precontracted and different selective and non- 
selective PDE inhibitors were added incremently. Three 
different PDE isoenzymes were characterized: PDE I 
(calmodulin-sensitive), PDE II (cGMP-stimulated), and 
PDE IV (cAMP-specific). All PDE inhibitors relaxed the 
strips dose-dependently, with the 50% effective concen- 
trations (ECs0) being 30 gM for papaverine, 40 ~tM for za- 
prinast, 25 gM for quazinone, and 0.1 gM for rolipram. 
The ureter-relaxing effect of the PDE IV inhibitor at low 
concentrations, combined with its low-level effect on the 
systemic irculatory parameters, may open the possibility 
of using selective PDE IV- inhibitors in the treatment of 
ureteral colics or for ureteral stone passage. 
The incidence of urinary-tract s one disease in Germany is 
estimated to be 0.1%, with the prevalence for primary 
stones being 4%-5%. In the case of an uncomplicated re- 
nal or ureteral stone, the application of intravenous anal- 
gesics is the most useful means of relieving the pain [1, 
2]. With respect to the potential beneficial effect of 
ureteral relaxation on stone passage, some spasmolytic 
agents uch as phentolamine and orciprenaline have been 
shown to dilate the ureteral lumen at the level of an artifi- 
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cial concretion and, thus, to allow increased fluid flow be- 
yond the concretion. 
Many drugs have been used in ureteral colic manage- 
ment [3], but the drug that can relief pain and facilitate 
stone passage with minimal systemic side effects is miss- 
ing. One family of drugs used in the treatment of ureteral 
colics is the prostaglandin synthetase inhibitor [4]. These 
drugs not only relieve the pain but also facilitate stone 
passage [5]. The most effective mode of administration is 
the intravenous route, but in 55% of cases, side effects oc- 
cur. However, since these drugs also decrease the renal 
blood flow, they may induce renal failure, especially in 
obstructed kidneys [4, 5]. 
In recent years there has been increasing evidence that 
cyclic nucleotides [cyclic adenosine monophosphate 
(cAMP) and cyclic guanidine monophosphate (cGMP)] 
play an important role in the regulation of smooth-muscle 
tone [6]. cAMP increases the rate of Ca 2+ uptake into the 
storage site (sarcoplasmic reticulum) and causes a de- 
crease in the intrasarcoplasmic Ca2+ concentration, lead- 
ing to smooth-muscle r laxation [7]. The degragation of 
cyclic nucleotides i catalyzed not by a single enzyme but 
by a number of different isoenzymes of phosphodiesterase 
(PDE). Recent data suggest that five different isoenzymes 
exist and that these show distinct species and tissue dif- 
ferences [8]. Since specific inhibitors of the isoenzyme 
families have been described, selective inhibition of a 
specific PDE isoenzyme may induce the same therapeutic 
effect with fewer side effects as compared with nonselec- 
tive inhibition. 
The aim of our study was to characterize PDE isoen- 
zymes in the human ureter. Since the mere presence of an 
enzyme does not give any information on its functional 
significance, an in vitro study was done to examine the ef- 
fect of selective PDE inhibitors on isolated ureteral 
smooth-muscle strips. 
Material and methods 
Ureters were taken from patients who had undergone radical 
nephrectomy for a malignant renal tumor. Preoperatively, radioiso- 
tope nephrograms were routinely done an  showed a renal function 
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of at least 100 ml/min in the renal units from which the ureters were 
taken. After excision, the ureter specimens were immediately placed 
in ice-cold saline, minced, and placed in 8 weight vols. of PDE iso- 
lation buffer [10 mM TRIS, 2 mM MgC12, 1 mM dithiothreitol 
(DTT); pH 7.5]. After ultraturrax homogenization, the homogenate 
was centrifuged at 40,000 g for 30 min. The supernatant was used as 
a source of cytosolic PDE. The pellet was resuspended and again 
centrifuged to cover the remaining cytosolic PDE. The resultant pel- 
let was used to determine the PDE activity of the particulate fraction. 
Separation of PDE isoenzymes was performed using anion-ex- 
change chromatography [diethylaminoethyl (DEAE)-Sephacel 
column, 16 x 150 mini. Q-Sepharose (column, 10 x 125 mm) was 
used only in rechromatography. The columns were equilibrated 
with 10-15 bed vols. of buffer A (70 mM sodium acetate, 1 mM 
DTT; pH 6.5). The filtered (0.45 p,m) supernatant (4-6 ml) was 
applied using a 500-gl injection loop, with multiple injections be- 
ing delivered via a manual-injection valve. After a 2-bed-vol. 
wash, the bound material was eluted from the column using a lin- 
ear 70- to 1,000-ram sodium acetate gradient (0-100% buffer B: 
1,000 mM sodium acetate, 1 mM DTT; pH 6.5) in 240 min at a 
flow rate of 1 ml/min. UV absorption was detected at 254 nm. 
Fractions (3 ml) were collected and assayed for PDE activity. 
A modification of the assay method of Thompson et al. [9] and 
Lakey et al. [10] was used. In brief, the PDE present in the tissue 
extract cleave the 3",5"-phosphodiester bond of 3",5"-cAMP. A 
mixture of tritiated cAMP and normal cAMP was used as a sub- 
strate in the reaction. 5"-AMP was then converted to adenosine by 
the addition of nucleotidase from snake venom (Crotalus atrox). 
Tritiated adenosine was then precipitated with the anion-exchange 
resin. The resultant radioactivity of adenosine in the supernatant 
was measured in a beta counter after the addition of scintillation 
cocktail. This method is equally applicable to measurement of the 
hydrolysis of cGMP. All assays were performed in duplicate. The 
results were expressed as the amounts (in picomoles) of cyclic nu- 
cleotide hydrolyzed per milliliter of enzyme preparation per 
minute. Blank values were determined by adding the lution buffer 
at various ionic strenghts and a linear increase in activity was 
found. For calculations, these blank values were subtracted. 
mal reaction velocity) values were determined using the 
Lineweaver-Burke plotting method [11]. The following substrate 
concentrations were used: 100, 50, 37.5, 25, 12.5, 10, 7.5, 5, 2, 1.5, 
1, 0.5 and 0.1 gM. 
In vitro study 
For the in vitro study, ureters were directly placed in 4°C solution 
[potassium chloride, 4.6 raM; sodium bicarbonate 15 raM; sodium 
chloride, 119 raM; NaH2PO+ 1.2 rnM; magnesium chloride, 1.2 
raM; NarCa-ethylenediaminetetraacetic acid (EDTA), 0.1 raM; 
and glucose, 20 g]. The solution was gassed with carbogen (95% 
O2, 5% CO2) to adjust the pH to 7.4 before 1.5 mM CaC12 was 
added. All experiments were performed within 24 h of tissue exci- 
sion; previous control studies had shown that ureteral strips pre- 
served in this manner gave r sults identical to those obtained with 
specimens taken immediately from the operating room. Ureteral 
strips of 8- to 10-mm length and 3- to 4-mm width were mounted 
in a 10-ml organ-bath chamber (transducer, Statham force dis- 
placement transducer; amplifier, Semmeg 9000 Burster Gernsbach 
Prgzisionsmegtechnik; polygraph, Linseis type 2025) and continu- 
ously gassed with carbogen at 37°C. 
The preparations were allowed to equilibrate for 60-90 min, 
during which time the passive tension was set at 0.5 g by repeated 
adjustments. Then 80 mM KC1 was added to precontract the strips; 
after a stable degree of tension had been reached (plateau), the test 
substances were added. Several concentrations were tested on each 
strip until a relaxation of more than 50% was reached. In a pilot 
study, ureteral strips were contracted by different pharmacological 
agents (noradrenalin, prostaglandin 2-alpha carbachol, endothe- 
line, 20 mM KC1), but none of them produced a stable contraction 
sufficient for relaxation studies. 
Each PDE inhibitor was tested on three different ureteral 
preparations. Responses were expressed as the percentage of re- 
laxation of KCl-induced contractions. Cumulative concentration- 
response curves were generated for each substance, and the ECs~ 
values (drug concentrations producing 50% reiaxation) were deter- 
mined graphically by linear interpolation. 
PDE isoenzyme characterization 
Except for measurements of enzyme kinetics, the substrate con- 
centration used was 1 gM for cAMP and cGMP. The substrate 
specificity of all fractions was tested by incubating every second 
fraction with cAMP or cGMP, thus possibly allowing the identifi- 
cation of PDE IV or V. To examine the effect of calcium and 
calmodulin on cAMP/cGMP hydrolysis, calcium chloride (10 p.M) 
and bovine-heart calmodulin 40 nM were added to the fractions. 
The presence of calmodulin-sensitive PDE (PDE I) was thus eval- 
uated. To examine the effect of cGMP on cAMP hydrolysis, 5 gM 
cGMP was added to the assay tubes. The presence of cGMP-in- 
hibited (PDE III) or cGMP-stimulated (PDE II) PDE was evalu- 
ated using this test. 
Statistical analysis 
The results are presented as mean values _+ SEM (n denotes the 
number of preparations examined). Student's two-tailed t-test was 
used for between-group comparisons of data. A probability level 
of < 0.05 was accepted as significant. All statistical evaluations 
were calculated using the STAT ¥ IEW 512 program (Brain Power 
Inc., USA). 
Results 
PDE isoenzyme determination 
Effect of various PDE inhibitors 
Various PDE inhibitors were tested at concentrations ranging from 
10 `7 to 10 -4 M to distinguish the inhibition of PDE hydrolytic ac- 
tivity in the peak fractions. Papaverine was used as the nonselec- 
tive PDE inhibitor, and the selective PDE inhibitors were zaprinast 
(PDE I/V inhibitor), quazinone (PDE III inhibitor), and rolipram 
(PDE IV inhibitor). No selective inhibitor of PDE II is available. 
Dose-response curves were generated and ICso values (concentra- 
tions producing 50% inhibition of substrate hydrolysis) were de- 
termined graphically. 
Enzyme kinetics 
Michaelis constants Kmvalues, i.e., the substrate concentration that 
produces 50% of the maximal reaction velocity) and Vma x (maxi- 
In all, 82% ot the total homogenate  PDE act iv ity was 
found in the supernatant fraction. The act iv ity o f  the par- 
t iculate fract ion was 18%. The ratio of  cAMP to cGMP 
hydrolys is  (at the l -gM initial concentrat ion)  in the super- 
natant fract ion was 1.1:1. In two exper iments  evaluated,  
86.9% of  the total act iv ity appl ied to the anion exchange 
co lumn was recovered  after elut ion in di f ferent fract ions 
F igure 1 shows the hydrolys is  of  either cAMP or cGMP 
init iated by the fract ions eluted f rom the DEAE-Sephace l  
column. The effect o f  the addit ion of  5 ~tM cGMP to the 
fractions on cAMP hydrolys is  is depicted in Fig. 2. As il- 
lustrated, three di f ferent peaks with hydrolyt ic  act iv ity 
were reso lved f rom human ureter extracts by DEAE-  
Sephacel  chromatography.  
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Fig. 1. Hydrolysis of cAMP and cGMP. Aliquots of the fractions 
from DEAE-Sephacel were measured to determine the hydrolytic 
activity in vitro. Samples were measured in duplicate and are rep- 
resentative of two different ureter preparations. Three peaks can 
be determined with different specificity for either cAMP (filled 
squares) or cGMP (open triangles) 
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Fig.2. Effect of cGMP on cAMP hydrolysis, cAMP hydrolysis 
was measured after the addition of 5 gM cGMP to the assay tubes. 
Samples were measured in duplicate and are representative of two 
different ureter preparations. Note the inhibitory effect of cGMP in 
peak I and its strong stimnlatory effect in peak II. - -m- -  cAMP; 
--~---  cAMP + cGMP 
Peak I (fractions 27-35) which eluted at low ionic 
strenght, catalyzed the hydrolysis of cAMP and cGMP 
with a preference for cGMP as the substrate (ratio, 4.1:1). 
The addition of 40 nM bovine-heart calmodul in and 
10 gM CaC12 activated cAMP and cGMP hydrolysis by a 
factor of up to 1.5 (Fig. 3). These findings suggest the 
presence of calmodulin-sensit ive PDE, or PDE I. Peak I 
exhibited a Michael ian kinetic behavior, with the Km 
value for cGMP being 1.02 gM (Table 1). Although the 
hydrolysis of cAMP in peak I was low, a slight inhibition 
by 5 gM cGMP was noted, which suggests the presence of 
cGMP- inhibited PDE, or PDE III (Fig. 2). To determine 
the presence of  PDE III in peak I, rechromatography us- 
ing Q-Sepharose was performed, and PDE I (calmodulin- 
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Fig. 3. Effect of calcium and calmodulin on cGMP a (upper panel) 
and cAMP b (lower panel) hydrolysis. Calmodulin (40 nM) and 
calcium chloride (10 gM) were added to active fractions and the 
standard assay was performed. Fractions 30 and 31 showed an 
increase in hydrolytic activity; in all other fractions measured, 
hydrolysis was not changed, a • cGMP; [] cGMP + 40 nM cal- 
modulin, b • cAMP; [] cAMP + 40 nM calmodulin 
Table 1. Km values and reaction velocity of peaks I-I I i  
Km value Vma x 
(pmol m1-1 min -1) 
Peak I 1.02 gM 8.30 
Peak II 5.10 ~tM 52.63 
Peak III 1.43 gM 6.25 
From the dose-response curve generated for cAMP hydrolysis of 
the peak fractions after DEAE-Sephacel separation, Kn~ and Vma× 
values were evaluated. The substrate concentrations u ed ranged 
from 0.1 to 100 gM. Data represent mean values for duplicate 
determinations obtained  two representative experiments using 
different ureter preparations 
sensitive PDE) was detected in the only peak eluted from 
the column. The addition of cGMP did not alter the hy- 
drolysis of  cAMP (data not shown). Peak II (fractions 
52-66) catalyzed the hydrolysis of cAMP and cGMP to a 
comparable degree. Since 5 ~tM cGMP stimulated cAMP 
hydrolysis by a factor of up to almost 7 (Fig. 2), peak II 
was designated as PDE II (cGMP-st imulated PDE). The 
Km value for this peak was 5.10 ~tM (Table 1). Peak II I 
(fractions 70-76) hydrolyzed only cAMR with the K m 
value being 1.43 gM (Table 1). This result suggests the 
presence of PDE IV (cAMP-specif ic  PDE) in peak III. 
The effect of different PDE inhibitors, namely, pa- 
paverine (nonselective PDE inhibitor), quaziuone (selec- 
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Table 2. Inhibitory effect of various PDE inhibitors on different 
peaks of PDE activity in human ureter preparations 
PDE inhibitor ICs0 (gM) 
Peak I Peak I Peak II Peak III 
(cGMP) (cAMP) 
Papaverine 4.5 17 3 2 
Quazinone 50 7 70 > 100 
Rolipram > 100 100 > 100 0.5 
Zaprinast 0.35 2 25 50 
The inhibitory effect of various PDE inhibitors on different peaks 
of PDE activity in human ureter preparations was measured using 
1.0 gM cAMP as a substrate. For peak I, 1.0 gM cGMP was also 
used. Data represent IC50values for duplicate determinations ob- 
tained in two representative experiments using different ureter 
preparations a calculated using incremental concentrations of PDE 
inhibitors 
tive PDE III inhibitor), rolipram (selective PDE IV in- 
hibitor), and zaprinast (PDE V and I inhibitor) was tested. 
The fraction with the highest activity in each peak (frac- 
tion 31 for peak I, fraction 62 for peak II, and fraction 74 
for peak III) was used. Table 2 summarizes the ICs0 values 
determined from the concentration-response curves. 
Papaverine was found to exert relatively potent inhibi- 
tion, but it showed nonselective inhibitory effects on all 
forms of PDE. At a concentration of 10 .4 M, it produced 
100% inhibition of all PDE isoforms except PDE I with 
cAMP as the substrate. Zaprinast was the most potent in- 
hibitor of peak I, with ICs0 values falling within the sub- 
micromolar range. This findings supports the presence of 
PDE I in peak I. Quazinone also inhibited peak I dose- 
dependently, especially when cAMP served as the sub- 
strate. No selective inhibition was found for peak II. Only 
papaverine inhibited the PDE activity at relatively low 
concentrations (ICs0, 3 gM). All other inhibitors tested 
could not induce 50% inhibition even at the maximal con- 
centrations tested (104M). This finding is in accordance 
with the presence of PDE II in this peak. Rolipram, the se- 
lective inhibitor of PDE IV, inhibited peak III selectively 
with the ICs0 value being 0.5 gM. Quazinone and zapri- 
hast inhibited peak III at ICs0 values of > 100 gM and the 
IC50 value for papaverine was 2 gM. The presence of PDE 
IV in this peak is supported by these results. 
Organ bath study 
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Fig. 4. Relaxant effect of cumulatively increasing concentrations 
of the nonselective PDE inhibitor papaverine and the selective in- 
hibitors quazinone, zaprinast, and rolipram on human ureteral 
strips precontracted with 80 mM KC1. Each data point represents 
the mean value + SEM for 3-7 ureteral strips. - -D - -  Papaverine; 
- -~- -  quazinone; ----O-- zapparinast; --At-- rolipram 
Table 3. Relaxant effect of various PDE inhibitors n isolated 
human ureteral strips preconcentrated with 80 mM KC1 
PDE Relaxation (%) ECs0 
inhibitor Inhibitor concentration (gM) 
10 -7 M 10 -6 M 10 s M 10 .4 M 
Papaverine 0 0 5.0 100 30 
Quazinone 1.5 11.8 24.8 86.8 25 
Zaprinast 0 0 8.1 75.5 40 
Rolipram 56.8* 77.1" 89.7* 100 0.1 
Data represent mean values for 3-7 ureteral strips. The ICs0 value 
was determined graphically 
* P < 0.05 (between-group analysis) 
centration of 10 4 M. The ECs0 value was 30 gM. Quazi- 
none showed a relaxant effect at an ICs0 value of 25 gM. 
The maximal concentration (10 -4 M) produced 86.8% + 
5.4% relaxation. Zaprinast relaxed the human ureteral 
strips in this study at an ECs0 value fo 40 ~tM, and the 
maximal concentration used (10 -4 M) induced 75.5% _+ 
12.9% relaxation. Rolipram concentration of 10 .7 M re- 
laxed the preparations by 56.8% + 5.5%, and a concentra- 
tion of 10 -4 M produced 100% relaxation (Fig.4). The re- 
laxant potency (ECs0) of all the inhibitors tested is listed 
in Table 3. 
None of the ureteral muscle strips showed any sponta- 
neous activity. The human ureteral strips were precon- 
tracted with 80 mM KC1 and produced a maximal tonus 
contraction of 7.5 + 0.9 mN (n = 14). All PDE inhibitors 
tested induced a dose-dependent relaxation with different 
potency. At the highest concentration tested (10 -4 M), pa- 
paverine and rolipram were capable of inducing total and 
maximal relaxation of the muscle strips with similar po- 
tency (P < 0.05). Quazinone and zaprinast relaxed the 
strips with lower potency (P < 0.05; Table 3). Papaverine 
started to relax the strips at a concentration f 10 -5 M; this 
nonselective inhibitor produced 100% relaxation at a con- 
Discussion 
Our results demonstrate the presence of at least three 
cyclic nucleotide PDE isoenzymes in the human ureter. In 
our study, the supernatant was used as the source of PDE 
representing the cytosolic fraction. However, we are 
aware that the particulate fraction of smooth-muscle c lls 
has funcitonal significance, although we found only 18% 
activity there. Weiss and Wheeler [12] prepared cytoso- 
lic fractions from guinea-pig ureters by centrifuging the 
homogenate at 50,000 g; centrifugation of the super- 
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natant at 100,000 g has failed to sediment additional ac- 
tivity. 
The presence of PDE I in peak I was shown in our 
study, where calmodulin stimulated the activity of this 
PDE isoenzyme by a factor of almost 2. Zaprinast selec- 
tively inhibited hydrolysis at low concentrations (ICs0, 
0.35-2 gM). As expected, kinetics studies performed in 
this peak revealed a PDE with high affinity for cGMP 
(K m, 1.02 gM). For most PDE I preparations from mam- 
malian tissues, the calmodulin-stimulated activity is 6-20 
times greater than the basal activity. In the present study 
the activity of PDE I was stimulated by a factor of only 2 
by calmodulin, but stimulation was reproducible in differ- 
ent tissue extracts. A similar result has also been obtained 
in the dog ureter [13]. The reason for this wide variation 
in enzyme stimulation by calmodulin is not known, but a 
number of factors may contribute to this variation [14]. 
Moreover, the extent of calmodulin stimulation is also de- 
pendent on the assay conditions. In our study, nonsaturat- 
ing substrate concentrations were used. In this series, the 
presence of PDE I in peak I was further supported by the 
selective inhibition of this peak by zaprinast, whereas the 
other selective PDE inhibitors tested inhibited the activity 
only at very high concentrations, with the IC50 values be- 
ing > 50 gM. 
A second peak hydrolyzed cAMP and cGMP to a com- 
parable degree. The addition of cGMP stimulated cAMP 
hydrolysis by several orders of magnitude; this suggests 
the presence of PDE II (cGMP-stimulated PDE) in peak 
II. The most potent inhibitor for this peak was papaverine 
(a nonselective PDE inhibitor; IC50, 2 gM). The selective 
PDE inhibitors tested did not significantly inhibit cAMP 
hydrolysis except at very high concentrations (ICs0, 25- 
100 gM). Since no selective inhibitor of PDE II has thus 
far been identified, the above findings support he pres- 
ence of PDE II in peak II. Our studies on the hydrolytic 
properties of peak II showed that this peak contains a low- 
affinity (K m, 5.10 gM) PDE. The main characteristic of 
PDE II is that cAMP hydrolysis is markedly stimulated by 
micromolar concentrations of cGMR The mechanism of 
this activation is believed to result from the association f 
cGMP with an allosteric binding site on the enzyme, lead- 
ing to a conformational change at a separate hydrolytic 
binding site [15]. 
The third peak of activity (peak III) selectively hy- 
drolzyed cAMR It was not stimulated by calmodulin and 
was therefore designated as PDE IV, or cAMP-specific 
PDE. The Km value (1.43 gM) was also in accordance 
with the results of other studies on PDE IV [16]. Further 
support for this conclusion was its sensitivity to inhibition 
by rolipram (ICs0, 0.5 ~tM), which is categorized as a PDE 
IV-selective inhibitor, and its complete insensitivity to 
cGMP and to the PDE III-selective inhibitor quazinone 
(IC50, > 100 gM). 
Therefore, our results show the presence of three PDE 
isoenzymes in the human ureter. Since many factors influ- 
ence the functional significance of an enyzme, in vitro 
studies were done to determine the PDE isoenzyme whose 
inhibition by a specific PDE inhibitor would lead to the 
strongest ureteral relaxation at the lowest concentration. 
No spontaneous contraction was found in our ureter 
preparations. This absence of spontaneous contractions i
consistent with the findings of other researchers. How- 
ever, spontaneous and regular contractions of ureteral 
strips have also been reported. It may be hypothesized 
that anoxia may have provoked spontaneous ureteral ac- 
tivity in some cases, as it occurred more often in abnormal 
or damaged ureters [4]. 
Papaverine relaxed the strip preparations at an ECs0 
value of 20 gM. It must be noted that this nonselective 
PDE inhibitor produced only 5% relaxation at concentra- 
tions of 10 -5 M, whereas 100% relaxation was reached at 
concentrations of 10 -4 M(Fig. 4). This type of "slope" may 
have therapeutic significance, since an excessive or inad- 
equate ffect may occur if the dose of the drug is not care- 
fully adjusted [5]. Although the relaxant effect of pa- 
paverine on the isolated human ureter was first shown 
long ago [6], there are conflicting reports regarding its ef- 
fectiveness for the relief of ureteral colic [7]. Our findings 
suggest a narrow therapeutic range for papaverine regard- 
ing ureteral relaxation, with relatively high doses being 
needed to produce a significant degree of relaxation. This 
underscores the limited use of papaverine in the treatment 
of ureteral colic. 
Zaprinast relaxed the ureteral strips in a dose-depen- 
dent manner but with low potency (ECs0, 40 ~tM), despite 
the observation that it inhibited PDE activity in the ureter 
homogenates at a low concentration (ICs0, 0.35-2 gM). 
Quazinone also showed a weak relaxing effect on the hu- 
man ureteral smooth muscle only at high concentrations. 
This findings confirms the lack of PDE III in the ureteral 
homogenates. 
Rolipram (PDE IV inhibitor) was the most potent drug 
in relaxing ureteral strips (EC50, 0.1 gM). At the lowest 
concentration tested (10 -7 34), relaxation of 56.8% was 
achieved. As shown in Fig. 4, rolipram effectively inhib- 
ited PDE IV activity at low concentrations (ICs0, 0.1 gM). 
This close correlation between the functional response 
(relaxation) of the tissue and the biochemical response 
(PDE IV activity inhibition), suggests that PDE IV isoen- 
zymes are physiologically important in the regulation of 
ureteral smooth-muscle tone. In contrast o rolipram, the 
other selective inhibitors tested showed no such correla- 
tion. 
Our experiments were performed using isolated 
ureteral preparations in which basal turnover rates of 
cyclic nucleotides are low; therefore, relatively high con- 
centrations of PDE inhibitors are needed to elevate cyclic 
nucleotide levels enough to produce a change in tissue 
tone. In contrast to this in vitro situation, cyclic nucleotide 
turnover ates are more elevated in vivo, with PDE in- 
hibitors consequently having a much greater effect on tis- 
sue levels of cyclic nucleotides [9]. 
Specifically, there are three effects of PDE IV in- 
hibitors that should be useful in the treatment of ureteral 
colics. First, relaxation of the ureter at the site of the im- 
pacted stone should relieve the colic pain and facilitate 
stone passage. Second, the edema and inflammation that 
usually accompany ureteral stones are eased by PDE IV 
inhibitors. Finally, rolipram induces minimal cardiovascu- 
lar effects when given at the required oses, enabling the 
systemic application of this drug for this purpose. A num- 
291 
bet of substances different from rolipram are classified as 
PDE IV inhibitors and have been clinically investigated. 
These drugs have been used in the treatment of asthma 
bronchiale, inflammation, and depression. It remains to be 
determined as to whether these agents act on the human 
ureter in a manner comparable with that of rolipram. We 
think that our study may open a new approach for the 
treatment of ureteral colic. Despite the likelihood that there 
are species differences in the PDE-isoenzyme pattern of 
the ureter, animal studies should be done to examine a 
possible ureter-selective effect of rolipram in vivo. 
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